Table 1.
Comparison of demographic, clinical, and laboratory characteristics of laboratory-confirmed and clinically diagnosed COVID-19 patients
| Laboratory-confirmed COVID-19 (n=69) | Clinically diagnosed COVID-19 (n=51) | P | ||
|---|---|---|---|---|
| Patient demographics | ||||
| Age (years), mean±SD | 50.9±14.0 | 50.9±18.8 | 0.997 | |
| Gender (M/F) | 43/26 | 24/27 | 0.139 | |
|
| ||||
| Clinical findings | ||||
| Fever (≥37.3°C ) | 21/69 (30.4) | 13/51 (25.5) | 0.697 | |
| Dry cough | 43/69 (62.3) | 27/51 (52.9) | 0.399 | |
| Sore throat | 23/69 (33.3) | 18/51 (35.3) | 0.977 | |
| Fatigue | 20/69 (29.0) | 17/51 (33.3) | 0.757 | |
| Dyspnea | 16/69 (23.2) | 14/51 (27.5) | 0.749 | |
|
| ||||
| History of suspicious contact | 18/69 (26.1) | 11/51 (21.6) | 0.722 | |
|
| ||||
| History of travel abroad | 2/69 (2.9) | 2/51 (3.9) | 1.000 | |
|
| ||||
| Laboratory tests | ||||
|
| ||||
| WBC count (normal range, 4–10 ×103/uL) | Low | 12/68 (17.6) | 4/50 (8.0) | < 0.001 |
| Normal | 52/68 (76.5) | 29/50 (58.0) | ||
| High | 4/68 (5.9) | 17/50 (34.0) | ||
|
| ||||
| Lymphocyte count (normal range, 1–4 ×103/mm3) | Low | 19/68 (27.9) | 12/50 (24.0) | 0.882 |
| Normal | 47/68 (69.1) | 36/50 (72.0) | ||
| High | 2/68 (2.9) | 2/50 (4.0) | ||
|
| ||||
| Neutrophil to lymphocyte ratio, mean±SD | 2.69±1.84 | 4.74±4.44 | 0.112 | |
|
| ||||
| CRP (normal range, 0.00–0.50 mg/L) | Normal | 16/69 (23.2) | 17/48 (35.4) | 0.216 |
| High | 53/69 (76.8) | 31/48 (64.6) | ||
|
| ||||
| LDH (normal range, 125–220 U/L) | Normal | 16/54 (29.6) | 15/44 (34.1) | 0.799 |
| High | 38/54 (70.4) | 29/44 (65.9) | ||
Data are presented as n/N (%) unless otherwise noted.
M/F, Male/Female; WBC, white blood cell; CRP, C-reactive protein; LDH, lactate dehydrogenase.